# GaStroEsophageal effeCt of indobUfen Versus aspiRin in Patients Undergoing Dual antiplatElet Therapy

> **NCT04129008** · PHASE4 · UNKNOWN · sponsor: **Beijing Anzhen Hospital** · enrollment: 88 (estimated)

## Conditions studied

- Coronary Artery Disease
- Gastroesophageal Reflux Disease

## Interventions

- **DRUG:** Indobufen and aspirin mimetic
- **DRUG:** Aspirin and indobufen mimetic

## Key facts

- **NCT ID:** NCT04129008
- **Lead sponsor:** Beijing Anzhen Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-17
- **Primary completion:** 2020-09-30
- **Final completion:** 2020-12-31
- **Target enrollment:** 88 (ESTIMATED)
- **Last updated:** 2019-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04129008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04129008, "GaStroEsophageal effeCt of indobUfen Versus aspiRin in Patients Undergoing Dual antiplatElet Therapy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04129008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*